Celularity (CELU) Capital Leases (2020 - 2021)
Celularity's (CELU) quarterly Capital Leases came in at $28.1 million in Q4 2021, up 1.63% year-over-year from $27.6 million in Q4 2020, and little changed quarter-over-quarter from $28.0 million in Q3 2021.
Powered by 
Analysis
Celularity (CELU) Capital Leases (2020 - 2021) Analysis & Trends
Celularity (CELU) has reported Capital Leases for 2 consecutive years, with $28.1 million the latest figure, recorded in Q4 2021.
- On a quarterly basis, Capital Leases rose 1.63% year-over-year to $28.1 million in Q4 2021; TTM through Dec 2021 was $28.1 million, a 1.63% increase from a year earlier, with the FY2021 full-year figure at $28.1 million, up 1.63% from the prior year.
- Capital Leases was $28.1 million for Q4 2021 at Celularity, roughly flat from $28.0 million in the prior quarter.
- Over five years, Capital Leases peaked at $28.1 million in Q4 2021 and troughed at $27.6 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.20 Bn | 9.36 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.35 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.56 Bn | 2.59 Bn | 251.50 Mn |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.17 Bn | 1.37 Bn | 251.87 Mn |
| 9 | Vericel | 1.93 Bn | 1.76 Bn | 56.40 Mn |
| 10 | Celularity | 36.61 Mn | 30.43 Mn | -3.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 28.09 Mn |
| Sep 30, 2021 | 28.02 Mn |
| Dec 31, 2020 | 27.63 Mn |